LOTUS EYE HOSPITAL AND INSTITUTE LIMITED Lotus Eye Hospital and Institute Limited Stock Bombay S.E.
Equities
LOTUSEYE
INE947I01017
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60 INR | -1.85% |
|
-4.75% | -28.01% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 389M 4.66M | Sales 2023 | 470M 5.64M | Capitalization | 1.22B 14.6M |
|---|---|---|---|---|---|
| Net income 2022 | 29M 347K | Net income 2023 | 40M 479K | EV / Sales 2022 | 2.64 x |
| Net cash position 2022 | 75.55M 905K | Net cash position 2023 | 76.6M 918K | EV / Sales 2023 | 2.43 x |
| P/E ratio 2022 |
36.9
x | P/E ratio 2023 |
29.9
x | Employees | 313 |
| Yield 2022 |
0.94% | Yield 2023 |
0.85% | Free-Float | 35.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.85% | ||
| 1 week | -4.75% | ||
| Current month | -4.75% | ||
| 1 month | -3.77% | ||
| 3 months | -18.09% | ||
| 6 months | -32.28% | ||
| Current year | -28.01% |
1 week
60.00
64.00
1 month
57.5065.73
Current year
44.1095.00
1 year
44.10110.90
3 years
38.65110.90
5 years
16.05110.90
10 years
5.57110.90
| Managers | Title | Age | Since |
|---|---|---|---|
K. S. Ramalingam
CEO | Chief Executive Officer | 74 | 20-07-30 |
| Director of Finance/CFO | 66 | 22-05-24 | |
M Achuth Menon
CMP | Compliance Officer | - | 22-02-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 85 | 07-10-15 | |
Yogesh Shah
BRD | Director/Board Member | 75 | 07-10-15 |
| Director/Board Member | 47 | 09-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 60 | -1.85% | 2 303 |
| 24-05-08 | 61.13 | -1.40% | 1,897 |
| 24-05-07 | 62 | +0.05% | 11,872 |
| 24-05-06 | 61.97 | -1.84% | 2,273 |
| 24-05-03 | 63.13 | +0.22% | 4,116 |
Delayed Quote Bombay S.E., May 09, 2024 at 06:00 am EDT
More quotes
Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company operates primarily in the field of ophthalmology (Eye) and its related operations. It resolves a range of eye problems, such as refractive, cataract, cornea infections, ocular prosthesis, orbit and oculoplasty, glaucoma, keratoconus, computer vision syndrome, neuro ophthalmology, retinal disease/diabetic eye care, UVEA and ocular inflammation, zyoptix-ultimate, and binocular vision. The Company provides treatments through ReLEx SMILE, Lasik Eye Surgery, Epi-LASIK, Intralase, Supracor, Robotic Femto Laser Cataract Surgery (LRCS), Phacoemulsification, Paediatric Eye Care and Squint Surgery, and Micro Incision Cataract Surgery (MICS). The Company operates approximately seven centers at Peelamedu, R.S. Puram, Mettupalayam, Tirupur, Salem, Cochin, and Mulanthurthy.
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.39% | 16.61B | |
| +4.50% | 12.48B | |
| +4.48% | 11.7B | |
| +1.79% | 10.07B | |
| +27.89% | 8.59B | |
| -4.37% | 7.7B | |
| +21.11% | 7.3B | |
| +3.19% | 6.56B | |
| +47.50% | 4.55B |
- Stock Market
- Equities
- LOTUSEYE Stock
- LOTUSEYE Stock